We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Instill Bio Inc | NASDAQ:TIL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.08 | 0.71% | 11.30 | 10.43 | 11.65 | 11.7319 | 10.7689 | 11.33 | 12,339 | 01:00:00 |
From May 2022 to May 2024
By Josh Beckerman
Instil Bio Inc. shares were down 35% to $5.16 Friday afternoon.
Earlier Friday, the biopharmaceutical said that it received investigational new drug clearance from the U.S. Food and Drug Administration for ITIL-306, Instil's first genetically-engineered Costimulatory Antigen Receptor TIL therapy.
The company also said it will present findings from studies of anti-FOLR1 CoStAR T cells on June 5.
Truist lowered its price target on the shares to $25 from $32. Analyst Asthika Goonewardene said Truist updated its model following the company's May 16 earnings report.
Truist lowered its "peak 3L melanoma share" for the company to 20% from 30%.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
May 27, 2022 13:13 ET (17:13 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Instill Bio Chart |
1 Month Instill Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
